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Aim: To analyze the dosimetric factors affecting long-term renal function in patients with
gastric cancer following postoperative radiotherapy with concomitant chemotherapy to
the upper abdomen.
Methods: Between January 2005 and July 2010, 13 patients treated with three-dimensional
conformal radiotherapy and concurrent fluorouracil-based chemotherapy (CRT) were
included in this analysis. After a median follow-up of 55 months, creatinine, glomerular
filtration rate (GFR), total kidney and left kidney volumes, before and after CRT and mer-
captoacetyltriglycine (MAG3) scintigraphy, were used to evaluate the renal function and
were correlated with the dosimetrics data.
Results: Significant correlations were found in the loss of left kidney volume and V35 (20.6%)
(p ¼ 0.035) and V40 (15.7%) (p ¼ 0.031) and in the loss of relative functional contribution of
the main kidney and V35 Gy (p ¼ 0.027) and V40 Gy (p ¼ 0.019). In patients with a slightly
low basal GFR (n ¼ 6), the relative functional contribution of the left kidney significantly
decreased, regardless of the dosage.
Conclusion: Functional renal impairment without any clinical signs or symptoms can be
observed in low doses after radiotherapy. Careful treatment planning and a detailed evalu-
ation of the functional renal capacity before treatment may help to reduce late renal toxicity.
Copyright © 2015, The Egyptian Society of Radiation Sciences and Applications. Production
and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The kidney is one of the main dose-limiting organs during
abdominal irradiation in cancer patients. Radiation-induced
clinical renal injury to this late-responding tissue has been
previously described (Cassady, 1995; Flentje, Hensley,
Gademann, Menke, & Wannenmacher, 1993; Helal, Fick-
Brosnahan, Reed-Gitomer, & Schrier, 2012; Kost et al., 2002;
Verheij, Dewit, Valdes Olmos, & Arisz, 1994). The kidney has a
physiological compensatory capacity, and many clinical signs
and symptoms cannot be observed until the glomerular
filtration rate (GFR) significantly decreases (Cassady, 1995).
The tolerance limits for defining the probability of serious
insufficiency were also described (Emami, Lyman, Brown, &
Cola, 1991). However, the patient-related (i.e., diabetes, hy-
pertension, liver or heart failure and previous kidney insuffi-
ciency), treatment-related (i.e., chemotherapy, low doses of
radiotherapy) and organ-specific (spatial variation in radio-
sensitivity, compensatory capacity for both kidneys) effects
remain unclear and need to described (Dawson et al., 2010).
We aimed to analyze the functional changes in the kidney
over time and to examine their correlations with dose-volume
results in gastric cancer patients receiving adjuvant
chemoradiotherapy.2. Materials and methods
This retrospective study was approved by the Ethical Com-
mittee of Marmara University School of Medicine with the
protocol number of 09.2011.0031. Between January 2005 and
June 2010, 13 (12 male: 1 female) patients who had histologi-
cally proven, locally advanced (AJCC IB-IIIB) gastric cancer and
who had undergone an operation were recruited for the
analysis (Edge et al., 2010). Their median age was 61 (range,
48e74 years), and all of the patients followed were disease-
free, with no clinically diagnosed kidney insufficiency. There
were two patients had comorbidities (hypertension and dia-
betes) diagnosed before adjuvant radiotherapy.
2.1. Chemoradiotherapy
All patients underwent our center's routine procedure for
upper abdominal region tumors. The patients first underwent
a simulation in the supine position and then a treatment-
planning computed tomography scan (CT) with images
taken at 5-mm slice intervals. The data were transferred to a
treatment planning system (Eclipse v8.0 Varian Medical Sys-
tems, Palo Alto, USA), and 3D planning was performed for all
patients. Two opposite and equally weighted ante-
rioreposterior fields were used. Treatment was administered
with photons (18 MV) using a linear accelerator (Saturne 42,
800 series, General Electric, Buc, France). A total median dose
of 45 Gy (range, 45e50.4 Gy) in 25e28 daily fractions of 1.8 Gy
was delivered to the target (primary tumor site and regional
lymphatics). Concurrent chemotherapy was administered as
an IV bolus of 5-fluorourasil 400 mg/m2/day and leucovorin
20 mg/m2/day during the first four and last three fractions of
radiotherapy (Macdonald et al., 2001). Chemotherapy wasadministered to 84.6% of patients without any interruption
due to any toxicity. All patients had one cycle of chemo-
therapy before radiotherapy and one more cycle after con-
current treatment.
2.2. Kidney anatomy and function analysis
Kidney volumeswere calculated for the CT-simulation images
and last follow-up abdominal CT images using a standardized
formula (V ¼ p/6  height  width  length). The percentages
of difference between the two images were also calculated.
Creatinine clearance was calculated using the Cochroft for-
mula of glomerular filtration rate (GFR) [(140age)  kg/
72  creatinine] (www.kidney.org/professionals/kdoqi/gfr_
calculator.cfm). Serum creatinine was measured using the
kinetic color test (Jaffe method) for the quantitative determi-
nation of creatinine in human serum on Beckman Coulter
analysers. Reference intervals for serum creatinine were as
follows:
Male <50 years 74e110 mmol/L (0.84e1.25 mg/dL)
Male >50 years 72e127 mmol/L (0.81e1.44 mg/dL)
Female 58e96 mmol/L (0.66e1.09 mg/dL)
Patient serum samples were used to compare this Creati-
nine OSR6178 assay on the AU2700 against a commercially
available enzymatic creatinine assaywhich has demonstrated
equivalence to the IDMS reference method.
Renal insufficiency grading was performed according to
the recommendations of the American Kidney Society (www.
kidney.org/professionals/KDOQI/guidelines_commentaries.
cfm).
2.3. Dynamic renal scintigraphy with
mercaptoacetyltriglycine (MAG3)
Each patient was asked to drink aminimumof 500ml of water
15e30minbefore thescan.After the i.v. bolus injectionof 2mCi
Tc-99m MAG3 (Technescan MAG3™ Kit, Mallinckrodt Phar-
maceuticals, Ireland), images were acquired every second for
60 s in the perfusion phase and every 30 s for 23 min in the
extraction and excretion phases (Symbia® E Gamma Camera
System, Siemens, USA) according to European Association of
Nuclear Medicine dynamic renography guideline (Gordon,
Piepsz, & Sixt, 2011). The images were evaluated both visually
and semiquantitatively (split function, time to peak and time
from maximum activity to 1/2 maximum activity) by drawing
regions of interest around each kidney, both of which were
assumed to contribute equally to the total renal function (the
split functionwas50% forboth)before radiotherapy.According
to these terms, a split functionof the left kidneywas calculated
after therapy and was correlated with the other findings.
2.4. Dose-volume analysis
Dose volume histograms were derived from the treatment
plans for each patient. The percentages receiving 5 Gy (V5),
10 Gy (V10), 15 Gy (V15), 20 Gy (V20), 25 Gy (V25), 30 Gy (V30),
35 Gy (V35), 40 Gy (V40), maximum dose (Dmax) and mean
dose (Dmean) volumes for the total (combined) kidney and for
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change in creatinine and GFR; percentage losses in total kid-
ney volume and left kidney volume; and the percentage of
functional left kidney were also calculated.2.5. Statistical analysis
Paired sample t-tests were used to compare the pre- and post-
radiotherapy results of serum creatinine, GFR and kidney
volumes for each patient. The percentages of difference be-
tween pre- and post-radiotherapy creatinine, GFR, and kidney
volumes were evaluated. Spearman correlation analysis was
performed to assess the correlations between the percentages
of changes in these parameters and each of the dose-volume
results (V5 to V40, Dmax, and Dmean). Multivariate analysis
was performed for gender, age and comorbidity. Statistical
significance was set at p < 0.05.3. Results
The median follow-up was 55 months (range, 20e84 months).
The morphological and functional results of kidneys were
summarized in Table 1. There was no statistically significant
difference in the creatinine level changes. However, the
glomerular filtration rate (98.2 ± 22.8 mg/dL vs.
83.36 ± 15.8mg/dL, p¼ 0.03), total kidney volume (355 ± 72.6 cc
vs. 320.6 ± 74.9 cc, p ¼ 0.02) and left kidney volume
(185.7 ± 41.5 vs. 151.1 ± 46.02, p < 0.0001) were significantly
decreased during follow-up. All patients' basal GFR results
were higher than 60 ml/min. In six patients, the basal GFR
results were between 60 and 90ml/min (mean 80.7ml/min); in
seven patients, the basal GFR results were greater than 90 ml/
min (mean 117.6 ml/min). The percentages of changes in the
study parameters for all patients and for the low GFR group
are shown in Table 2. All of the correlation results are sum-
marized in Tables 3 and 4. According to the dose-volume re-
sults, there were correlations between V35 (20.6%) and the
percentages of left kidney volume loss (p ¼ 0.035) and left
kidney functional loss (p ¼ 0.027) and between V40 and the
percentages of left kidney volume loss (p ¼ 0.031) and func-
tional loss (p ¼ 0.019) (Table 3). In the low GFR group, V5
(45.2%, p ¼ 0.03), V10 (35%, p ¼ 0.02), V15 (30.1%, p ¼ 0.02), V20Table 1 e Comparison of renal function results for the
pre- and post-treatment periods.
Mean (±SD) p
Creatinine (mg/dL)
Before CRT 0.86 (±0.16) 0.28
After CRT 0.92 (±0.15)
Creatinine clearance (GFR) (mg/dL)
Before CRT 98.2 (±22.8) 0.03
After CRT 83.36 (±15.8)
Total kidney volume (cc)
Before CRT 355 (±72.6) 0.02
After CRT 320.6 (74.9)
Main kidney volume (cc)
Before CRT 185.7 (±41.5) <0.0001
After CRT 151.1 (±46.02)(27.2%, p ¼ 0.02), V25 (24.5%, p ¼ 0.02), V30 (22%, p ¼ 0.02), V35
(20.6%, p ¼ 0.02), V40 (15.7%, p ¼ 0.02) and Vmean (29.9%)
(p ¼ 0.008) were correlated with the percentage of left kidney
functional loss. A correlation was also noted between Vmean
and left kidney volume loss (p ¼ 0.045). Moreover, V10 (24.4%,
p ¼ 0.04), V15 (20.3%, p ¼ 0.01), V20 (18.2%, p ¼ 0.009), V25
(15.7%, p ¼ 0.009), V30 (13.4%, p ¼ 0.006), V35 (11.5%, p ¼ 0.007)
and V40 (9.3%, p ¼ 0.014) correlated with the percentage of
total kidney functional loss (Table 4). Onmultivariate analysis,
no significant results were found for these parameters.4. Discussion
None of the patients suffered from clinical renal insufficiency
after a median 55 months of follow-up in our study.
Conversely, the left kidney volume was decreased, as corre-
lated mostly with the higher doses of 35 Gy and 40 Gy. Due to
the dose-volume analysis, the volume loss in the left kidney
was also accompanied by a loss of functional impairment.
Here, we also used mercaptoacetyltriglycine (MAG3) which is
a tubular agent. It has a high renal extraction rate with an
improved image quality (even in patients with deteriorated
renal function) compared to the other agents. mercaptoace-
tyltriglycine is now the radiopharmaceutical of choice in dy-
namic renal scans, which were completed using the Tc-99m
MAG3 test (Gordon et al., 2011). In contrast, there were no
similar results considering the anatomical and functional
losses in both kidneys, which could be explained by the
compensatory functions of the kidneys. When lower doses of
irradiation were received partially by one kidney, the
remainder of that kidney and the opposite kidney demon-
strate an increase in glomerular filtrations and compensatory
functions (hyperfiltration). Therefore, as previously described,
the kidney tolerance dose is determined by the number of
tubule cells per nephron rather than the number of nephrons
per kidney (Emami et al., 1991). Still, such effectsmay progress
to glomerular sclerosis (Helal et al., 2012). Moreover, for partial
kidney irradiation, mean dose limit for both kidneys was
recommended to keep below 18 Gy (Nevinny-Stickel et al.,
2007). In our study, we found that the mean dose was 9.5 Gy
which was as low as recommended in literature. The
other reference doses that may be used as a predictor forTable 2 e Percentage changes in all patients and in GFR
low patients.
Mean (±SD)
All patients
n ¼ 13
GFR low group
n ¼ 6
Percentage of loss in whole
kidney volume (%)
12.33 14.95
Percentage of loss in left
kidney volume (%)
19.68 (±10.95) 20.27 (±12.43)
Percentage of loss in functional
role of left kidney (%)
10.15 (±9.35) 10.11 (±10.22)
Percentage of change in
creatinine (%)
13.17 (±14.09) 6.60 (±6.77)
Percentage of change in
clearance (%)
15.57 (±13.07) 9.33 (±8.99)
Table 3 e Correlation results for all patients (n ¼ 13).
Percentage of
change in
creatinine (%)
Percentage of
change in
clearance (%)
Percentage of
loss in total
kidney volume (%)
Percentage of
loss in left
kidney volume (%)
Percentage of
loss in functional
role of left kidney (%)
p r p r p r p r p r
Left kidney
V5 (45.7%) 0.457 0.227 0.286 0.320 0.517 0.19 0.122 0.451 0.129 0.444
V10 (35.01%) 0.679 0.127 0.491 0.21 0.72 0.1 0.067 0.522 0.055 0.543
V15 (30.1%) 0.83 0.066 0.625 0.149 0.725 0.088 0.071 0.516 0.089 0.490
V20 (27.2%) 0.95 0.019 0.7 0.116 0.872 0.05 0.067 0.523 0.072 0.514
V25 (24.5%) 0.957 0.017 0.8 0.077 0.986 0.006 0.052 0.549 0.068 0.521
V30 (22%) 0.957 0.017 0.8 0.077 0.986 0.006 0.052 0.549 0.068 0.521
V35 (20.6%) 0.914 0.033 0.858 0.055 0.823 0.069 0.035 0.588 0.027 0.609
V40 (15.7%) 0.733 0.10 1.0 0 0.68 0.127 0.031 0.599 0.019 0.636
Vmax (46.2%) 0.524 0.19 0.86 0.053 0.50 0.20 0.171 0.404 0.016 0.649
Vmean (9.5%) 0.99 0.003 0.77 0.089 0.943 0.02 0.056 0.542 0.054 0.545
Total kidney
V5 (32.9%) 0.351 0.282 0.136 0.436 0.487 0.21 0.344 0.286 0.577 0.171
V10 (24.4%) 0.893 0.041 0.439 0.235 0.347 0.28 0.329 0.294 0.239 0.352
V15 (20.3%) 0.986 0.006 0.5 0.2 0.4 0.25 0.28 0.324 0.23 0.358
V20 (18.2%) 0.943 0.022 0.457 0.227 0.481 0.21 0.20 0.374 0.197 0.383
V25 (15.7%) 0.143 0.022 0.457 0.227 0.481 0.21 0.209 0.374 0.197 0.383
V30 (13.4%) 0.986 0.006 0.502 0.205 0.475 0.21 0.177 0.399 0.18 0.394
V35 (11.5%) 0.943 0.022 0.5 0.2 0.426 0.24 0.174 0.4 0.18 0.397
V40 (9.3%) 0.7 0.11 0.76 0.094 0.865 0.05 0.06 0.534 0.132 0.441
Vmax (46.5%) 0.015 0.65 0.064 0.52 0.979 0.008 0.1 0.475 0.114 0.46
Vmean (29.9%) 0.857 0.056 0.638 0.144 0.351 0.18 0.221 0.365 0.406 0.252
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in Table 5. Therefore, it seems that all findings of our study
was lower than the results of previous studies (Jansen et al.,
2007; Nevinny-Stickel et al., 2007 and Welz et al., 2007). Our
study showed that, despite of the low doses, there may beTable 4 e Correlation results in low basal GFR patients (n ¼ 6).
Percentage of
change in
creatinine (%)
Percentage of
change in
clearance (%)
Percent
loss in
kidney vo
p r p r p
Left kidney
V5 (45.7%) 0.398 0.322 0.235 0.441 0.865
V10 (35.01%) 0.509 0.254 0.277 0.407 0.831
V15 (30.1%) 0.509 0.254 0.277 0.407 0.831
V20 (27.2%) 0.509 0.254 0.277 0.407 0.831
V25 (24.5%) 0.509 0.254 0.277 0.407 0.831
V30 (22%) 0.509 0.254 0.277 0.407 0.831
V35 (20.6%) 0.509 0.254 0.277 0.407 0.831
V40 (15.7%) 0.509 0.254 0.277 0.407 0.831
Vmax (46.2%) 0.592 0.2 0.982 0.009 0.81
Vmean (9.5%) 0.625 0.19 0.338 0.362 0.728
Total kidney
V5 (32.9%) 0.965 0.017 0.60 0.203 0.831
V10 (24.4%) 0.828 0.085 0.398 0.322 0.865
V15 (20.3%) 0.897 0.051 0.425 0.305 0.831
V20 (18.2%) 0.761 0.119 0.323 0.373 0.966
V25 (15.7%) 0.761 0.119 0.323 0.373 0.966
V30 (13.4%) 0.845 0.077 0.4 0.315 0.949
V35 (11.5%) 0.761 0.119 0.425 0.3 0.831
V40 (9.3%) 0.948 0.02 0.612 0.197 0.932
Vmax (46.5%) 0.5 0.25 0.895 0.052 0.631
Vmean (9.5%) 0.86 0.69 0.723 0.138 0.828found impairment of functional capacity in kidneys. One of
themost important sign of renal insufficiency is the decreases
of creatinine clearance. In one study, authors showed that the
creatinine clearance decreases if half of one kidney's dose
exceeds 26 Gy (Willett et al., 1986). Another study reportedage of
total
lume (%)
Percentage of
loss in left
kidney volume (%)
Percentage of
loss in functional
role of left kidney (%)
r p r p r
0.067 0.099 0.583 0.034 0.706
0.083 0.077 0.617 0.02 0.748
0.083 0.077 0.617 0.02 0.748
0.083 0.077 0.617 0.02 0.748
0.083 0.077 0.617 0.02 0.748
0.083 0.077 0.617 0.02 0.748
0.083 0.077 0.617 0.02 0.748
0.083 0.077 0.617 0.02 0.748
0.09 0.345 0.358 0.133 0.541
0.136 0.045 0.678 0.008 0.812
0.083 0.18 0.483 0.12 0.546
0.067 0.38 0.333 0.04 0.681
0.083 0.35 0.350 0.01 0.765
0.017 0.22 0.450 0.009 0.807
0.017 0.22 0.450 0.009 0.807
0.02 0.168 0.502 0.006 0.827
0.08 0.170 0.5 0.007 0.815
0.034 0.15 0.52 0.014 0.775
0.18 0.347 0.356 0.073 0.624
0.085 0.235 0.441 0.127 0.547
Table 5 e Comparisons of the dose limits for radiation-induced kidney injury in different studies.
Variable Dose-volume relations Reference Our study
Partial kidney irradiation
Bilateral kidneys Mean kidney dose <18 Gy Nevinny-Stickel et al., 2007 9.5 Gy
Bilateral kidneys V28Gy < %20 Nevinny-Stickel et al., 2007 14.5%
Bilateral kidneys V20Gy < %32 Jansen et al., 2007 18.2%
Bilateral kidneys V12Gy < %55 Welz et al., 2007 22.5%
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ceeds 10e20 Gy in 0.8e1.25 Gy per fraction (Schneider, Marti,
Von Briel, Frey, & Greiner, 1999). In our study, we observed a
decline in creatinine clearance for all patients. It was more
prominent in patients that the pre-treatment GFR resultswere
60e90 ml/min.
Based on these data, conformal treatment recommends
that V35 be kept under 20.5%, and V40, below 15.7%, in order to
reduce the anatomical and functional kidney damage within
the treatment field. V28 for bilateral renal irradiation is rec-
ommended to be kept under 20%; our study used the value of
14.5%. Several reasons could have accounted for our inability
to demonstrate significant dose-volume proposals for the
bilateral kidneys, among which are the low number of pa-
tients and the compensatory features of the kidney.
During treatments that place the kidneys within the
radiotherapy field, it is not routine to modify the dosage in
patients due to a mild to moderate decrease in the GFR. In our
subgroup analysis, patients with mildly or moderately low
baseline GFR values had prominent functional impairment in
the left kidney at low doses. The present analysis of all pa-
tients showed no significant effect on the bilateral kidneys,
although the designation of kidney damage in this group
included not only the left kidney but also both kidneys. Ac-
cording to these guidelines, our study showed that even in the
range of a so-called “safe dose” a significant effect may occur
on kidneys of patients with functional basal causes. There-
fore, based on our results, the baseline renal function of pa-
tients should be examined in detail before radiotherapy.
In conclusion, functional injury may help to predict the
clinical insufficiency for kidneys after chemoradiotherapy.
This effect is more prominent in patients who have mildly or
moderately low GFR. Hence, basal renal functions should be
assessed, and comorbid factors should be considered before
radiotherapy. Renal toxicity seems to act as an iceberg; not
only for high doses but also for low doses and more attention
may be recommended during treatment planning.Conflict of interest
We declare that we have no conflict of interest.r e f e r e n c e s
Cassady, J. R. (1995). Clinical radiation nephropathy. International
Journal of Radiation Oncology Biology Physics, 31, 1249e1256.
Dawson, L. A., Kavanagh, B. D., Paulino, A. C., Das, S. K.,
Miften, M., Li, X. A., et al. (2010). Radiation-associated kidneyinjury. International Journal of Radiation Oncology Biology Physics,
76, 108e115.
Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., &
Trotti, A. (Eds.). (2010). AJCC cancer staging manual (7th ed.).
New York, NY: Springer.
Emami, B., Lyman, J., Brown, A., & Cola, L. (1991). Tolerance of
normal tissue to therapeutic irradiation. International Journal of
Radiation Oncology Biology Physics, 21, 109e122.
Flentje, M., Hensley, F., Gademann, G., Menke, M., &
Wannenmacher, M. (1993). Renal tolerance to
nonhomogenous irradiation: comparison of observed effects
to predictions of normal tissue complication probability from
different biophysical models. International Journal of Radiation
Oncology Biology Physics, 27, 25e30.
Gordon, I., Piepsz, A., & Sixt, R. (2011). Auspices of Paediatric
Committee of European Association of Nuclear Medicine.
Guidelines for standard and diuretic renogram in children.
European Journal of Nuclear Medicine and Molecular Imaging., 38,
1175e1188.
Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B., & Schrier, R. W.
(2012). Glomerular hyperfiltration: definitions, mechanisms
and clinical implications.Nature ReviewsNephrology, 8, 293e300.
Jansen, E. P., Saunders, M. P., Boot, H., Oppedjik, V.,
Dubbelman, R., Porritt, B., et al. (2007). Prospective study on
late renal toxicity following postoperative chemoradiotherapy
in gastric cancer. International Journal of Radiation Oncology
Biology Physics, 67, 781e785.
Kost, S., Dorr,W.,Keinert,K.,Glaser, F.H., Endert, G.,&Hermann,T.
(2002). Effect of dose and dose-distribution in damage to the
kidney following abdominal radiotherapy. International Journal
of Radiation Oncology Biology Physics, 78, 695e702.
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A.,
Estes, N. C., Stemmermann, G. N., et al. (2001).
Chemoradiotherapy after surgery compared with surgery
alone for adenocarcinoma of the stomach or gastroesophageal
junction. New England Journal of Medicine, 345, 725e730.
Nevinny-Stickel,M., Poljanc,K.,Forthuber,B.C.,Heute,D.,Posch,A.,
Lechner, J., et al. (2007). Optimized conformal paraaortic lymph
node irradiation is not associated with enhanced renal toxicity.
Strahlentherapie und Onkologie, 183, 385e391.
Schneider, D. P., Marti, H. P., Von Briel, C., Frey, F. J., &
Greiner, R. H. (1999). Long-term evolution of renal function in
patients with ovarian cancer after whole abdominal
irradiation with or without preceding cisplatin. Annals of
Oncology, 10, 677e683.
Verheij, M., Dewit, L. G., Valdes Olmos, R. A., & Arisz, L. (1994).
Evidence for a renovascular component in hypertensive
patients with late radiation nephropathy. International Journal
of Radiation Oncology Biology Physics, 30, 677e683.
Welz, S., Hehr, T., Kollmannsberger, C., Bokemeyer, C., Belka, C.,
Budach, W., et al. (2007). Renal toxicity of adjuvant
chemoradiotherapy with cisplatin in gastric cancer.
International Journal of Radiation Oncology Biology Physics, 69,
1429e1435.
Willett, C. G., Tepper, J. E., Orlow, E. L., & Shipley, W. U. (1986).
Renal complications secondary to radiation treatment of
upper abdominal malignancies. International Journal of
Radiation Oncology Biology Physics, 12, 1601e1604.
